Eingabe löschen




HIT to LEAD to Preclinical Candidate development of a Transcription Repressor Inhibitory Compound (TRIC) that increases antibiotic susceptibility of multidrug resistant staphylococci

Auf einen Blick

  • Projektleiter/in : Prof. Dr. Rainer Riedl
  • Projektteam : Dr. Mathieu Chellat, Luka Raguz
  • Projektvolumen : CHF 1'979'276
  • Projektstatus : abgeschlossen
  • Drittmittelgeber : KTI (KTI-Projekt / Projekt Nr. 15235.1 PFLS-LS)
  • Projektpartner : BioVersys AG
  • Kontaktperson : Rainer Riedl


A new and highly innovative treatment will be realized by a novel and patentable small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic staphylococci. The consortium integrates a screening platform, biophysical characterization of small molecules, medicinal chemistry, high-end characterization of mode of action and the in vivo mouse models, to develop initial HIT compounds into preclinical candidates.